Northwire Canada EditionTuesday, July 14, 2026

Sign in Subscribe

WDO 26.04 −0.9% FVI 11.84 −1.6% OM 1.75 −1.7% ETG 2.99 +0.0% ARTG 31.47 −4.6% LUC 0.163 +1.6% AFM 1.38 +0.0% IMG 20.95 −3.5% CPAU 0.150 +3.5% MMX 0.075 +7.1% IE 12.47 −2.4% SASK 1.09 −1.8% MOG 0.390 +2.6% XIM 0.070 −6.7% S 0.110 −29.0% OMI 0.300 −4.8% WDO 26.04 −0.9% FVI 11.84 −1.6% OM 1.75 −1.7% ETG 2.99 +0.0% ARTG 31.47 −4.6% LUC 0.163 +1.6% AFM 1.38 +0.0% IMG 20.95 −3.5% CPAU 0.150 +3.5% MMX 0.075 +7.1% IE 12.47 −2.4% SASK 1.09 −1.8% MOG 0.390 +2.6% XIM 0.070 −6.7% S 0.110 −29.0% OMI 0.300 −4.8%

Financings

Quantum BioPharma Provides Corporate Update

By The Northwire Desk — AI Analysis Mar 11, 2026 · 19:55 QNTM · 2.86 Quantum BioPharma Ltd.

QNTM · Price

Executive Summary

Quantum BioPharma revised the terms of its previously announced debenture units, lowering the conversion price to $3.00 per share and reducing the warrant exercise price to $3.75.
The number of warrants attached to each debenture unit was increased to 333.33, enhancing the potential upside for investors.
The debt settlement will be completed at the new reduced conversion price, reflecting a material adjustment to the offering structure.

Key Details

Conversion Price: Reduced from the original amount (unspecified) to $3.00 per Class B subordinate voting share.
Warrant Allocation: Increased to 333.33 warrants per debenture unit (up from the prior allocation).
Warrant Exercise Price: Decreased to $3.75 per warrant share.
Debt Settlement: Will be executed at the newly reduced conversion price of $3.00 per share.
Currency: All amounts are expressed in Canadian dollars.
Regulatory Notice: The securities are not registered under U.S. securities laws and may not be offered or sold to U.S. persons absent an exemption.

Notable Quotes

(No direct quotes were provided in the release.)

Read the original news release →

More from Quantum BioPharma Ltd.

Jun 26, 2026 · 08:30

Preclinical MS drug developer navigating FDA clinical hold while leveraging consumer supplement royalties.

Other Jun 25, 2026 · 08:30

Pre-revenue MS developer navigates FDA clinical hold while doubling down on myelin-repair narrative and consumer-health royalties

Other Jun 24, 2026 · 08:30

A pre-revenue biotech touting an MS drug's potential while its lead IND sits on clinical hold and the company stays silent on the setback in its latest marketing push.

Other Jun 22, 2026 · 08:30

Pre-revenue MS drug developer navigating FDA hold and negative equity while pursuing a $700M manipulation lawsuit.

Other Jun 01, 2026 · 19:30

A clinical hold on its lead MS drug and the sudden exit of a key director deal a double blow to Quantum BioPharma, erasing near-term catalysts and raising red flags about governance and data quality.

Regulatory May 18, 2026 · 03:00

Quantum BioPharma’s MS study hits halfway mark with early positive imaging signals, but the real catalyst remains an imminent FDA greenlight for its Phase 2 trial.